Adebrelimab

Monoclonal antibody

Approvedregulatory verdict

Evidence outlook

Approved: Perioperative treatment of resectable stage II, IIIA and IIIB NSCLC: with platinum-based... (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

Also in development:Small Cell Lung Cancer · Phase 3 · investigational in the US

Also approved (2)
CN
  • Perioperative treatment of resectable stage II, IIIA and IIIB NSCLC: with platinum-based chemotherapy before surgery, then adjuvant monotherapycls.cn
  • First-line extensive-stage small cell lung cancer with carboplatin and etoposide (registration notice dated 2023-03-07)db.antibodysociety.org
Product first approved 2023

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (20)
Non-Small Cell Lung Cancer
NCT07895238 · West China Hospital
2026-10-31 – 2034-12-31 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT07896005 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-12 – 2032-03 · Non Small Cell Lung Cancer
What this study did
NCT07822542 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2026-10-31 – 2031-12-31 · Carcinoma, Non-Small-Cell Lung
What this study did
Small Cell Lung Cancer
NCT05496166 · Shanghai Pulmonary Hospital, Shanghai, China
2023-08-01 – 2030-08-01 · Limited Stage Small Cell Lung Cancer
What this study did
NCT04691063 · Jiangsu HengRui Medicine Co., Ltd.
2021-01-22 – 2025-05-15 · Small-cell Lung Cancer
What this study did
Other / comorbidity
NCT07522151 · Shanghai Shengdi Pharmaceutical Co., Ltd
2026-05-07 – 2034-02 · Locally Advanced Gastric or Gastroesophageal Junction Cancer
What this study did
NCT07679360 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-09-02 – 2032-12 · Triple Negative Breast Cancer
What this study did
NCT07691762 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-11 – 2031-09 · Hepatocellular Carcinoma
What this study did
NCT07238569 · Sun Yat-sen University
2025-12-01 – 2031-05-23 · Nasopharyngeal Cancinoma (NPC), Nasopharangeal Cancer
What this study did
NCT07900789 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2026-10 – 2030-12-30 · Systemic Treatment-naïve Pancreatic Cancer
What this study did
NCT06618664 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2024-10-28 – 2030-12 · Advanced Hepatocellular Carcinoma
What this study did
NCT07393542 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-02-12 – 2030-10-31 · Locally Advanced or Metastatic Urothelial Carcinoma
What this study did
NCT07118527 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-08-18 – 2030-10 · Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma
What this study did
NCT07111832 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-08-20 – 2028-12 · PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer
What this study did
NCT07168200 · Shanghai Shengdi Pharmaceutical Co., Ltd
2025-10-17 – 2028-12 · Advanced Cervical Cancer
What this study did
NCT06913777 · Fudan University
2025-04-08 – 2027-04-15 · Neoadjuvant Therapy
What this study did
NCT04516681 · Fudan University
2024-12-01 – 2025-12-01 · Colorectal Cancer, Vitamin C, GLUT3
What this study did
Phase 2/3 (5)
Non-Small Cell Lung Cancer
Other / comorbidity
NCT07454720 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-03-23 – 2035-11 · Locally Advanced Resectable Rectal Cancer
What this study did
NCT06879145 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-04-25 – 2031-12 · Muscular Invasive Bladder Cancer (MIBC)
What this study did
NCT06861777 · YIN LI
2025-03 – 2031-05 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
NCT06791460 · Obstetrics & Gynecology Hospital of Fudan University
2025-03-18 – 2030-02-14 · Ovarian Cancer Recurrent
What this study did
Phase 2 (210)
Non-Small Cell Lung Cancer
NCT07836543 · Ming Chen
2026-09 – 2031-12 · Non-Small Cell Lung Cancer
What this study did
NCT07567326 · Peking University Cancer Hospital & Institute
2026-07 – 2030-12 · Non Small Cell Lung Cancer
What this study did
NCT06775275 · The First Affiliated Hospital of Guangzhou Medical University
2024-09-24 – 2029-12-31 · Resectable Lung Non-Small Cell Carcinoma
What this study did
NCT07890636 · Ruijin Hospital
2026-10-20 – 2029-12-31 · Lung Neoplasm Malignant
What this study did
NCT07704645 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-08 – 2029-12 · Resectable Non-small Cell Lung Cancer
What this study did
NCT07229729 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2025-11-24 – 2029-10 · Non-small Cell Lung Cancer
What this study did
NCT07778745 · Tianjin Medical University Cancer Institute and Hospital
2026-08-20 – 2029-08-30 · NSCLC
What this study did
NCT07281209 · Shanghai Chest Hospital
2025-12 – 2029-06 · NSCLC
What this study did
NCT06299371 · Liaoning Cancer Hospital & Institute
2024-04-15 – 2029-04-15 · Non Small Cell Lung Cancer
What this study did
NCT06844474 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-03-07 – 2028-12 · NSCLC
What this study did
NCT06480136 · Shanghai Pulmonary Hospital, Shanghai, China
2024-07-15 – 2028-02-15 · NSCLC
What this study did
NCT06467617 · Beijing Chest Hospital, Capital Medical University
2024-08-14 – 2027-03-01 · Non Small Cell Lung Cancer
What this study did
NCT07031154 · The First Affiliated Hospital of Xiamen University
2025-06-30 – 2027-02-01 · Non-Small Cell Lung Cancer, Adebrelimab, Apatinib
What this study did
NCT06336954 · Second Affiliated Hospital of Xi'an Jiaotong University
2024-03-30 – 2026-12-31 · Non Small Cell Lung Cancer
What this study did
NCT06700421 · Wei Zhou
2024-08-13 – 2026-12-31 · Unresectable Locally Advanced Non-small Cell Lung Cancer
What this study did
NCT07035392 · Zhangzhou Municipal Hospital
2025-06-20 – 2026-12-01 · Adebrelimab (SHR-1316), NSCLC, Chemotherapy
What this study did
NCT06182800 · The First Affiliated Hospital of Xinxiang Medical College
2023-12-27 – 2025-12-30 · Non-small Cell Lung Cancer
What this study did
NCT05932264 · Sun Yat-sen University
2023-07 – 2025-12 · NSCLC, Non-small Cell Lung Cancer
What this study did
NCT05738317 · Xiaorong Dong
2022-12-01 – 2024-12-01 · Non-small Cell Lung Cancer
What this study did
Small Cell Lung Cancer
NCT06773156 · Second Affiliated Hospital of Nanchang University
2024-11-01 – 2030-08-01 · Limited-stage Small Cell Lung Cancer (LS-SCLC)
What this study did
NCT07398560 · The Third Affiliated Hospital of Harbin Medical University
2026-02-01 – 2029-02-01 · Small Cell Lung Cancer
What this study did
NCT06614621 · Fujian Cancer Hospital
2025-02-01 – 2028-12-01 · Extensive-Stage Small Cell Lung Cancer
What this study did
NCT07798947 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2026-10-07 – 2028-12 · Limited-stage Small-cell Lung Cancer
What this study did
NCT07357532 · Peking University Cancer Hospital & Institute
2026-01-31 – 2028-10-30 · Small Cell Lung Carcinoma
What this study did
NCT06786312 · Fujian Cancer Hospital
2025-01-25 – 2028-09-25 · Small Cell Lung Cancer Extensive Stage
What this study did
NCT07909863 · Tianjin Medical University Cancer Institute and Hospital
2026-11-15 – 2028-09-01 · Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage
What this study did
NCT07200154 · Peking University Cancer Hospital & Institute
2025-09-30 – 2028-09 · Limited-stage Small-cell Lung Cancer, Concurrent Chemoradiation Therapy
What this study did
NCT07381543 · Peking University Cancer Hospital & Institute
2026-03 – 2028-08 · Localized Small Cell Lung Cancer
What this study did
NCT06562920 · Zhejiang Cancer Hospital
2024-07-24 – 2028-07-31 · Efficacy and Safety of Neoadjuvant Immunotherapy for Small Cell Lung Cancer
What this study did
NCT06914050 · Tianjin Medical University Cancer Institute and Hospital
2025-04 – 2028-04 · Lung Cancer, Small Cell, Limited-stage Small Cell Lung Cancer (LS-SCLC)
What this study did
NCT07069270 · Fujian Cancer Hospital
2025-09-01 – 2028-01-01 · Vunakizumab, Adebrelimab, Small Cell Lung Cancer
What this study did
NCT07583550 · Jiangmen Central Hospital
2026-07-20 – 2028-01-01 · Lung, Radiotherapy
What this study did
NCT06784206 · Peking University Cancer Hospital & Institute
2025-02 – 2028-01 · Small Cell Lung Cancer, Limited Stage, Hyperfractionated Accelerated Radiotherapy, Simultaneous Radiotherapy and Chemotherapy
What this study did
NCT06236997 · Henan Cancer Hospital
2024-02-10 – 2027-12-31 · Small Cell Lung Carcinoma
What this study did
NCT06739928 · Guangzhou Institute of Respiratory Disease
2025-01-01 – 2027-12-30 · Small Cell Lung Cancer Extensive Stage
What this study did
NCT07141264 · Tang-Du Hospital
2025-08-25 – 2027-12-30 · SCLC,Extensive Stage
What this study did
NCT06943235 · Fudan University
2025-04-25 – 2027-12-30 · Limited Stage Small Cell Lung Cancer
What this study did
NCT06306560 · Harbin Medical University
2024-03-15 – 2027-04-15 · Extensive-stage Small-cell Lung Cancer
What this study did
NCT06483282 · Jin Ying
2024-06-21 – 2026-12-31 · Small Cell Lung Cancer Limited Stage
What this study did
NCT06485544 · Tang-Du Hospital
2024-07-01 – 2026-12-30 · Small Cell Lung Cancer (SCLC)
What this study did
NCT06475209 · Tang-Du Hospital
2024-06-20 – 2026-12-20 · SCLC
What this study did
NCT06177925 · Nanfang Hospital, Southern Medical University
2023-12-10 – 2026-09-30 · Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Diseases, Respiratory Tract Diseases, Carcinoma, Bronchogenic, Bronchial Neoplasms, Lung Neoplasms, Small Cell Lung Carcinoma
What this study did
NCT04562337 · Shandong Cancer Hospital and Institute
2020-10-01 – 2024-10 · Extensive-stage Small Cell Lung Cancer
What this study did
NCT04647357 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
2020-11-27 – 2023-12-27 · Limited-stage Small Cell Lung Cancer, LS-SCLC
What this study did
Other / comorbidity
NCT07317778 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-02-15 – 2033-09-15 · Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast Cancer
What this study did
NCT07284992 · Shandong Provincial Hospital
2025-09-12 – 2033-06-30 · Rectal Cancer, Advanced Stage Colorectal Cancer, Radiotherapy
What this study did
NCT07622771 · Sun Yat-sen University
2026-05-26 – 2032-12-31 · Rectal Cancers
What this study did
Phase 1/2 (41)
Non-Small Cell Lung Cancer
NCT06754930 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-02-18 – 2027-12 · Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT05482568 · Jiangsu HengRui Medicine Co., Ltd.
2022-09-15 – 2026-12 · Advanced Non-small Cell Lung Cancer
What this study did
NCT06512051 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2024-07-30 – 2026-10 · Advanced or Metastatic Non-small Cell Lung Cancer
What this study did
NCT05416775 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2022-08-15 – 2026-06-30 · Advanced Non-small Cell Lung Cancer
What this study did
NCT06589778 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2024-09-27 – 2026-04-30 · Non-Small Cell Lung Cancer
What this study did
NCT06434103 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2024-10-10 – 2024-10-10 · Advanced Non-small Cell Lung Cancer
What this study did
Small Cell Lung Cancer
NCT06332950 · Baohui Han
2024-04-01 – 2027-04-01 · Extensive-stage Small-cell Lung Cancer
What this study did
NCT06597513 · Zhou Chengzhi
2024-12 – 2026-12 · Extensive Stage Small Cell Lung Cancer
What this study did
NCT04400188 · Jiangsu HengRui Medicine Co., Ltd.
2020-06-11 – 2022-01-15 · Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06417554 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2024-05-27 – 2031-12-31 · Advanced Solid Tumors
What this study did
NCT07239596 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-01-06 – 2030-12 · Advanced Renal Cell Carcinoma
What this study did
NCT07615283 · Sun Yat-sen University
2026-05-29 – 2030-10-29 · Relapsed or Refractory Peripheral T Cell Lymphoma, NKTCL
What this study did
NCT07806058 · Jiangsu HengRui Medicine Co., Ltd.
2026-10-15 – 2029-12-31 · Pancreatic Cancer
What this study did
NCT07736612 · Zhejiang University
2026-08-15 – 2029-12-30 · Pancreatic Cancer, RAS Mutations or Amplifications
What this study did
NCT06474455 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2024-07-02 – 2029-12 · Advanced Solid Tumors
What this study did
NCT07105592 · Fudan University
2025-05-13 – 2029-05-31 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT07595172 · West China Hospital
2026-04 – 2029-03 · Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced and Metastatic Pancreatic Cancer
What this study did
NCT07059221 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-07-11 – 2029-03 · Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
What this study did
NCT06427239 · Fudan University
2024-06-17 – 2028-03 · Pancreatic Cancer
What this study did
NCT07392541 · Tongji Hospital
2026-01-30 – 2028-01-30 · Advanced Biliary Tract Carcinoma
What this study did
NCT07229586 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2025-12-02 – 2027-12 · Solid Tumor
What this study did
NCT07296341 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2026-01-08 – 2027-12 · Locally Advanced or Metastatic Pancreatic Cancer With
What this study did
NCT07073534 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2025-07-24 – 2027-12 · Patients With Advanced or Metastatic Malignant Tumors
What this study did
NCT07890701 · Second Affiliated Hospital of Wenzhou Medical University
2026-10-20 – 2027-11-01 · Histiocytosis,Langerhans-Cell
What this study did
NCT06703177 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-02-18 – 2027-07-01 · Advanced Solid Tumors
What this study did
NCT06639347 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2024-11-04 – 2027-05-31 · Advanced Urothelial Carcinoma
What this study did
NCT07136142 · Jiangsu HengRui Medicine Co., Ltd.
2025-09-23 – 2027-02 · Malignant Solid Tumor
What this study did
NCT06776770 · Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
2024-08-03 – 2026-12-31 · Gastric Cancer
What this study did
NCT06741020 · Zhejiang Cancer Hospital
2025-03-01 – 2026-12-30 · Hepatocellular Carcinoma (HCC)
What this study did
NCT06840002 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-03-18 – 2026-12 · Ovarian Cancer
What this study did
NCT06373133 · West China Hospital
2024-05-01 – 2026-11-01 · Colorectal Cancer
What this study did
NCT06454448 · Tianjin Medical University Cancer Institute and Hospital
2024-06-15 – 2026-11 · Adebrelimab (SHR-1316), Decitabine, Metastatic Pancreatic Cancer
What this study did
NCT06222879 · Shandong Suncadia Medicine Co., Ltd.
2024-02-20 – 2026-10-31 · Breast Cancer
What this study did
NCT06474468 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2024-06-20 – 2026-10 · Advanced or Metastatic Esophageal Cancer
What this study did
NCT06592287 · Xianglin Yuan
2024-09-30 – 2026-09-30 · Advanced Gastric Cancer
What this study did
NCT06385678 · Jiangsu HengRui Medicine Co., Ltd.
2024-07-05 – 2026-08 · Advanced KRAS G12D Mutant Solid Tumors
What this study did
NCT05444088 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2022-08-02 – 2026-06-30 · Advanced Hepatocellular Carcinoma
What this study did
NCT05924997 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-07-01 – 2026-06-01 · Advanced Hepatocellular Carcinoma
What this study did
NCT06092268 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2023-10 – 2025-12 · Advanced Solid Tumors
What this study did
NCT06439589 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2024-06-12 – 2025-12 · Advanced Solid Tumors
What this study did
NCT05794477 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2023-04-28 – 2024-08-20 · Advanced Solid Tumor
What this study did
Phase 1 (25)
Non-Small Cell Lung Cancer
NCT06963502 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2025-05-30 – 2030-04-30 · Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer
What this study did
NCT06594874 · Jiangsu Hansoh Pharmaceutical Co., Ltd.
2024-10-31 – 2027-01-01 · Non-Small Cell Lung Cancer, Advanced Solid Tumors
What this study did
NCT06735508 · Guangdong Provincial People's Hospital
2025-01 – 2026-12 · NSCLC
What this study did
NCT06685653 · Nanjing Tianyinshan Hospital
est. completion 2026-11-30 · NSCLC
What this study did
Small Cell Lung Cancer
NCT07886047 · Second Xiangya Hospital of Central South University
2026-05-29 – 2029-12-31 · Small Cell Lung Cancer (SCLC)
What this study did
NCT07892625 · Hansoh BioMedical R&D Company
2026-11-15 – 2029-09-15 · Extensive Stage Small Cell Lung Cancer (ES-SCLC)
What this study did
NCT07009457 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-06-16 – 2028-09 · Widespread Small Cell Lung Cancer
What this study did
NCT07063407 · Shanghai Hansoh Biomedical Co., Ltd
2025-07-31 – 2027-05-31 · Extensive Stage Small Cell Lung Cancer (ES-SCLC)
What this study did
NCT04041011 · Jiangsu HengRui Medicine Co., Ltd.
2019-09-17 – 2021-04-23 · Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06181032 · First Affiliated Hospital of Fujian Medical University
2023-12-23 – 2029-02-23 · Biliary Tract Malignancies
What this study did
NCT06699576 · Hansoh BioMedical R&D Company
2024-12-20 – 2028-12-30 · Osteosarcoma, Soft Tissue Sarcoma (STS)
What this study did
NCT06350006 · Shanghai Hengrui Pharmaceutical Co., Ltd.
2024-05-29 – 2028-12-30 · CLDN18.2-positive Advanced Solid Tumor
What this study did
NCT06332170 · Hansoh BioMedical R&D Company
2024-04-26 – 2028-05-30 · Advanced Solid Tumor
What this study did
NCT06336707 · Hansoh BioMedical R&D Company
2024-04-11 – 2028-04-08 · Advanced Solid Tumors
What this study did
NCT06156267 · Fudan University
2024-01 – 2027-03 · Pancreatic Cancer
What this study did
NCT06902792 · Second Affiliated Hospital of Wenzhou Medical University
2025-02-06 – 2026-02-02 · Histiocytosis, Langerhans-Cell
What this study did
NCT05942378 · Fudan University
2023-07-01 – 2025-12-01 · Advanced Solid Tumors
What this study did
NCT06225921 · West China Hospital
2023-12-29 – 2025-01-15 · Esophageal Squamous Cell Carcinoma
What this study did
NCT05082545 · Atridia Pty Ltd.
2021-11-23 – 2024-02-12 · Advanced Malignant Tumors
What this study did
NCT05198817 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2022-02-22 – 2023-06-30 · Advanced Malignant Tumors
What this study did
NCT05048134 · Jiangsu HengRui Medicine Co., Ltd.
2021-10-25 – 2023-05-23 · Advanced Malignancies
What this study did
NCT03995472 · Jiangsu HengRui Medicine Co., Ltd.
2020-02-14 – 2023-01-12 · Advanced Malignancies
What this study did
NCT04979390 · Jiangsu HengRui Medicine Co., Ltd.
2021-08-10 – 2022-07-31 · Tumor
What this study did
NCT03474289 · Jiangsu HengRui Medicine Co., Ltd.
2018-03-01 – 2019-10-31 · Tumor
What this study did
NCT03133247 · Atridia Pty Ltd.
2017-06-01 – 2019-07-05 · Advanced Solid Tumors
What this study did
Phase 4 (2)
Other / comorbidity
NCT06192186 · Yang Jianjun, PhD
2023-12-30 – 2025-12-31 · Locally Advanced Gastric Adenocarcinoma
What this study did
NCT06417606 · Zhiyong Huang
2024-05-30 – 2025-05-30 · Intrahepatic Cholangiocarcinoma
What this study did
Early phase / not applicable (8)
Small Cell Lung Cancer
NCT06853678 · Tianjin Medical University Cancer Institute and Hospital
2025-02-28 – 2027-03-01 · Extensive Stage Small Cell Lung Cancer (ES-SCLC)
What this study did
NCT06480864 · Yunpeng Liu
2024-08-09 – 2026-08 · Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT05132790 · Shengjing Hospital
2023-09-25 – 2028-12-31 · Breast Cancer
What this study did
NCT06893887 · Nanjing Tianyinshan Hospital
2025-05-22 – 2028-12-15 · Hepatocellular Carcinoma(HCC)
What this study did
NCT07430579 · The Second Hospital of Shandong University
2024-12-09 – 2028-06-30 · Pathological Complete Remission, Objective Response Rate, Immune-related Adverse Events, Quality of Life
What this study did
NCT07388095 · Tianjin Medical University Cancer Institute and Hospital
2026-02-15 – 2028-02-28 · ESCC
What this study did
NCT06613113 · Ningbo Medical Center Lihuili Hospital
2024-08-07 – 2027-07-31 · MSS Metastatic Colorectal Cancer
What this study did
NCT06420908 · Hebei Medical University Fourth Hospital
2024-05-30 – 2027-05-30 · Esophageal Squamous Cell Carcinoma
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Non-Small Cell Lung Cancer
NCT07560358 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2026-05-01 – 2030-12-31 · NSCLC (Advanced Non-small Cell Lung Cancer)
What this study did
Phase 2 (2)
Non-Small Cell Lung Cancer
NCT07863167 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2026-10-30 – 2030-12-30 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
Appears in other studies (5)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Other / comorbidity
NCT06672133 · Jinming Yu
2024-12 – 2029-12 · Extensive Stage Lung Small Cell Carcinoma
What this study did
Phase 2 (4)
Small Cell Lung Cancer
Other / comorbidity
NCT07789379 · Wei Jiang
2026-10-01 – 2029-10-01 · Glioblastoma
What this study did
NCT07554768 · Chen Chunyan
2026-05-01 – 2029-05-01 · Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma
What this study did
NCT07028281 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-07-08 – 2028-12 · Malignant Solid Tumors
What this study did

Competitive landscape

This mechanism is crowded: 12 other tracked programmes target it, 4 of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Adebrelimab: this drugPhase 3Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
Avelumab
Approved(overall)
Monoclonal antibodyPD-L1
not yet graded(overall)
No reviewed efficacy summary in this indication
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Abp 234Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Aglatimagene BesadenovecPhase 3Gene therapy / editingHerpes simplex virus thymidine kinase (HSV-tk) gene productnot yet gradedNo reviewed efficacy summary in this indication
EnvafolimabPhase 3Monoclonal antibodyPD-L1Weak signal
NCT05068427: Primary endpoint ORR 6.7% (2/30); DCR 50% (15/30); median PFS 3.5 months
Fetrastobart VedotinPhase 3Antibody–drug conjugatePD-L1not yet gradedNo reviewed efficacy summary in this indication
Obrixtamig
Phase 3(overall)
Multispecific antibodyDLL3 (Delta-like ligand 3) x CD3not yet gradedNo reviewed efficacy summary in this indication
PumitamigPhase 3Multispecific antibodyPD-L1 and VEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Risvutatug RezetecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
SerplulimabPhase 3Monoclonal antibodyPD-1Weak signal
NCT04033354: At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67).
NCT03952403: Final analysis in nonsquamous NSCLC: median overall survival reached 26.8 months for Hetronifly (serplulimab) plus chemotherapy compared with 20.3 months for chemotherapy alone, a 34% reduction in the risk of death (HR=0.66, 95% CI: 0.52-0.83, P<0.001); median PFS was 11.0 months in Group B versus 5.7 months in the chemotherapy-only arm. No statistical difference was observed for Group A compared to Group B (HR=1.12, p=0.3628).
Sugemalimab (Cejemly)Phase 3Monoclonal antibodyPD-L1Reliable signal
NCT03728556: Progression-free survival (BICR-assessed), GEMSTONE-301: median PFS 10.5 months (sugemalimab) vs 6.2 months (placebo); HR 0.65, 95% CI 0.50-0.84
NCT03789604: Sugemalimab plus chemotherapy improved investigator-assessed PFS at interim analysis: median 7.8 vs 4.9 months, stratified HR 0.50.
TislelizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
HLX43Phase 2/3Antibody–drug conjugatePD-L1not yet gradedNo reviewed efficacy summary in this indication
AL8326Phase 2Small moleculeAurora B / FGFR / VEGFR (multi-kinase)not yet gradedNo reviewed efficacy summary in this indication
Ifinatamab DeruxtecanPhase 2Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
TagitanlimabPhase 2Monoclonal antibodyPD-L1not yet gradedNo reviewed efficacy summary in this indication
Quaratusugene Ozeplasmid (Reqorsa)Phase 1/2Gene therapy / editingTUSC2 (tumor suppressor gene replacement)not yet gradedNo reviewed efficacy summary in this indication
Tambotatug PelitecanPhase 1/2Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
177Lu-RAD204Phase 1RadiopharmaceuticalPD-L1not yet gradedNo reviewed efficacy summary in this indication
BPI-371153Phase 1Small moleculePD-L1not yet gradedNo reviewed efficacy summary in this indication
IBC-Ab002
Phase 1(overall)
Monoclonal antibodyPD-L1
Partial signal(overall)
No reviewed efficacy summary in this indication

Large race: only the 81 furthest-along competitors are listed; 531 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(175 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Adebrelimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (22)
November 2026 (2)
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-11-30 · NCT06685653 · CT.gov ↗
What to watch
Phase 2GC/GEJCRecruiting
Est. primary completion 2026-11-30 · NCT07770113 · CT.gov ↗
What to watch
December 2026 (20)
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12 · NCT06735508 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT05482568 · CT.gov ↗
What to watch
Phase 1/2Ovarian CancerRecruiting
Est. primary completion 2026-12 · NCT06840002 · CT.gov ↗
What to watch
Phase 2Carcinoma, HepatocellularRecruiting
Est. primary completion 2026-12 · NCT06454578 · CT.gov ↗
What to watch
Phase 2Unresectable Biliary Tract CarcinomaRecruiting
Est. primary completion 2026-12 · NCT06749730 · CT.gov ↗
What to watch
Phase 2Advanced Malignant TumourRecruiting
Est. primary completion 2026-12 · NCT06915142 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT06844474 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2026-12-01 · NCT07035392 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-01 · NCT06483282 · CT.gov ↗
What to watch
Phase 2Solid Cancer, Lymphopenia, Radiotherapy, Immune Checkpoint InhibitorRecruiting
Est. primary completion 2026-12-01 · NCT07267234 · CT.gov ↗
What to watch
Phase 2Biliary Tract CarcinomaNot yet recruiting
Est. primary completion 2026-12-10 · NCT07062328 · CT.gov ↗
What to watch
Phase 1Osteosarcoma, Soft Tissue Sarcoma (STS)Not yet recruiting
Est. primary completion 2026-12-30 · NCT06699576 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-30 · NCT07141264 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerActive not recruiting
Est. primary completion 2026-12-30 · NCT06465563 · CT.gov ↗
What to watch
Phase 2Head and Neck Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2026-12-31 · NCT06199271 · CT.gov ↗
What to watch
Phase 2Pancreatic Cancer Metastatic to LiverRecruiting
Est. primary completion 2026-12-31 · NCT06531278 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerRecruiting
Est. primary completion 2026-12-31 · NCT06620848 · CT.gov ↗
What to watch
Phase 2TNBC - Triple-Negative Breast CancerNot yet recruiting
Est. primary completion 2026-12-31 · NCT06819319 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Gastro-esophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2026-12-31 · NCT06808971 · CT.gov ↗
What to watch
Phase 2Triple-negative Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT05076682 · CT.gov ↗
What to watch
2027 (72)
January 2027 (1)
Phase 2Neuroendocrine Carcinoma of the Bladder, Bladder CancerRecruiting
Est. primary completion 2027-01-01 · NCT06091124 · CT.gov ↗
What to watch
February 2027 (4)
Phase 1/2Malignant Solid TumorRecruiting
Est. primary completion 2027-02 · NCT07136142 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-02-01 · NCT07031154 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-02-25 · NCT07452601 · CT.gov ↗
What to watch
Early phase / not applicableESCCNot yet recruiting
Est. primary completion 2027-02-28 · NCT07388095 · CT.gov ↗
What to watch
March 2027 (9)
Phase 1/2Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-03 · NCT07059221 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-03 · NCT06861894 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2027-03 · NCT06547736 · CT.gov ↗
What to watch
Phase 2Advanced Breast CancerRecruiting
Est. primary completion 2027-03 · NCT06433609 · CT.gov ↗
What to watch
Phase 2Intrahepatic CholangiocarcinomaRecruiting
Est. primary completion 2027-03-01 · NCT06296563 · CT.gov ↗
What to watch
Phase 2GC/GEJCNot yet recruiting
Est. primary completion 2027-03-01 · NCT06684158 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-03-15 · NCT06306560 · CT.gov ↗
What to watch
Phase 2Resectable Intrahepatic Cholangiocarcinoma With High Risk of RecurrenceRecruiting
Est. primary completion 2027-03-31 · NCT06280508 · CT.gov ↗
What to watch
Phase 2Unresectable Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-03-31 · NCT06360042 · CT.gov ↗
What to watch
April 2027 (6)
Phase 2Intrahepatic Cholangiocarcinoma (Icc)Not yet recruiting
Est. primary completion 2027-04 · NCT06648525 · CT.gov ↗
What to watch
Phase 1/2Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-04-01 · NCT06332950 · CT.gov ↗
What to watch
Phase 2Solid TumorNot yet recruiting
Est. primary completion 2027-04-01 · NCT06537505 · CT.gov ↗
What to watch
Phase 2Biliary Tract Neoplasms ImmunotherapyRecruiting
Est. primary completion 2027-04-15 · NCT07704177 · CT.gov ↗
What to watch
Phase 2Biliary Tract Neoplasms ImmunotherapyRecruiting
Est. primary completion 2027-04-29 · NCT07670273 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2027-04-30 · NCT06943235 · CT.gov ↗
What to watch
May 2027 (6)
Phase 2Biliary Tract CancerNot yet recruiting
Est. primary completion 2027-05-01 · NCT06389500 · CT.gov ↗
What to watch
Phase 2Gastric Cancer/Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2027-05-01 · NCT06385873 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-05-19 · NCT06424899 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-05-30 · NCT06508229 · CT.gov ↗
What to watch
Phase 1/2Advanced Urothelial CarcinomaRecruiting
Est. primary completion 2027-05-31 · NCT06639347 · CT.gov ↗
What to watch
Phase 1/2Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-05-31 · NCT07105592 · CT.gov ↗
What to watch
June 2027 (12)
Phase 1/2Pancreatic CancerRecruiting
Est. primary completion 2027-06 · NCT06427239 · CT.gov ↗
What to watch
Phase 2Hepatocellular Carcinoma Non-resectableNot yet recruiting
Est. primary completion 2027-06 · NCT07192848 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2027-06 · NCT07131514 · CT.gov ↗
What to watch
Phase 2Gastroesophageal Adenocarcinoma, Gastric AdenocarcinomaRecruiting
Est. primary completion 2027-06-01 · NCT06985602 · CT.gov ↗
What to watch
Phase 2Intrahepatic Cholangiocarcinoma (Icc)Recruiting
Est. primary completion 2027-06-01 · NCT06925516 · CT.gov ↗
What to watch
Phase 2HNSCCNot yet recruiting
Est. primary completion 2027-06-01 · NCT07778732 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-06-15 · NCT06480136 · CT.gov ↗
What to watch
Phase 2Biliary Tract Cancer, Biliary Tract Cancer (CCA)Recruiting
Est. primary completion 2027-06-30 · NCT07135544 · CT.gov ↗
What to watch
Phase 2Oral Squamous Cell Carcinoma (OSCC), Neoadjuvant ChemoimmunotherapyNot yet recruiting
Est. primary completion 2027-06-30 · NCT07137858 · CT.gov ↗
What to watch
Phase 2Pancreatic Cancer MetastaticNot yet recruiting
Est. primary completion 2027-06-30 · NCT07230301 · CT.gov ↗
What to watch
Phase 2Biliary Tract NeoplasmsRecruiting
Est. primary completion 2027-06-30 · NCT07668453 · CT.gov ↗
What to watch
Early phase / not applicablePathological Complete Remission, Objective Response Rate, Immune-related Adverse Events, Quality of LifeRecruiting
Est. primary completion 2027-06-30 · NCT07430579 · CT.gov ↗
What to watch
July 2027 (4)
Phase 2Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence RiskNot yet recruiting
Est. primary completion 2027-07 · NCT07682272 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-07-25 · NCT06786312 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2027-07-31 · NCT06562920 · CT.gov ↗
What to watch
Phase 2Stomach NeoplasmsRecruiting
Est. primary completion 2027-07-31 · NCT07309185 · CT.gov ↗
What to watch
August 2027 (3)
Phase 3Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-08-01 · NCT05496166 · CT.gov ↗
What to watch
Phase 2Locally Advanced Hypopharyngeal CancerNot yet recruiting
Est. primary completion 2027-08-20 · NCT07137039 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-08-30 · NCT07778745 · CT.gov ↗
What to watch
September 2027 (3)
Phase 1Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-09 · NCT07009457 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-09-01 · NCT07909863 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerActive not recruiting
Est. primary completion 2027-09-30 · NCT06766019 · CT.gov ↗
What to watch
October 2027 (4)
Phase 1/2Locally Advanced or Metastatic Pancreatic Cancer WithRecruiting
Est. primary completion 2027-10 · NCT07296341 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerNot yet recruiting
Est. primary completion 2027-10 · NCT07691593 · CT.gov ↗
What to watch
Phase 1/2Histiocytosis,Langerhans-CellEnrolling by invitation
Est. primary completion 2027-10-01 · NCT07890701 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2027-10-30 · NCT07583550 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Lung CancerRecruiting
Est. primary completion 2027-11 · NCT07241767 · CT.gov ↗
What to watch
December 2027 (19)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-12 · NCT06754930 · CT.gov ↗
What to watch
Phase 1/2Solid TumorRecruiting
Est. primary completion 2027-12 · NCT07229586 · CT.gov ↗
What to watch
Phase 1/2Patients With Advanced or Metastatic Malignant TumorsRecruiting
Est. primary completion 2027-12 · NCT07073534 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12 · NCT07281209 · CT.gov ↗
What to watch
Phase 2HER2 Expression Gastric Cancer/Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2027-12 · NCT05671822 · CT.gov ↗
What to watch
Phase 2Advanced Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2027-12 · NCT07751341 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell Carcinoma, Immunotherapy, BiomarkersRecruiting
Est. primary completion 2027-12 · NCT06510660 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-01 · NCT06614621 · CT.gov ↗
What to watch
Phase 2Pancreatic Cancer Non-resectable, Pancreatic Cancer MetastaticNot yet recruiting
Est. primary completion 2027-12-01 · NCT06916975 · CT.gov ↗
What to watch
Early phase / not applicableHepatocellular Carcinoma(HCC)Recruiting
Est. primary completion 2027-12-15 · NCT06893887 · CT.gov ↗
What to watch
Phase 1CLDN18.2-positive Advanced Solid TumorRecruiting
Est. primary completion 2027-12-30 · NCT06350006 · CT.gov ↗
What to watch
Phase 2Pancreatic Cancer, Neoadjuvant TherapyNot yet recruiting
Est. primary completion 2027-12-30 · NCT06177522 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Neuroendocrine TumorsNot yet recruiting
Est. primary completion 2027-12-31 · NCT06764368 · CT.gov ↗
What to watch
Phase 2Esophageal Cancer (EsC)Recruiting
Est. primary completion 2027-12-31 · NCT06869213 · CT.gov ↗
What to watch
Phase 2ESCCNot yet recruiting
Est. primary completion 2027-12-31 · NCT07584031 · CT.gov ↗
What to watch
Phase 2Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer …Recruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
Phase 2Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-12-31 · NCT07718490 · CT.gov ↗
What to watch
Phase 2Esophageal CancerRecruiting
Est. primary completion 2027-12-31 · NCT07733830 · CT.gov ↗
What to watch
2028 (51)
January 2028 (6)
Phase 2Cholangiocarcinoma, Biliary Tract CancerNot yet recruiting
Est. primary completion 2028-01-01 · NCT07561775 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell Carcinoma (ESCC)Recruiting
Est. primary completion 2028-01-01 · NCT07595770 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell Carcinoma (ESCC)Recruiting
Est. primary completion 2028-01-01 · NCT07638436 · CT.gov ↗
What to watch
Phase 2HER2-negative Breast CancerNot yet recruiting
Est. primary completion 2028-01-15 · NCT07466927 · CT.gov ↗
What to watch
Phase 1/2Advanced Biliary Tract CarcinomaRecruiting
Est. primary completion 2028-01-30 · NCT07392541 · CT.gov ↗
What to watch
Phase 3Locally Advanced or Metastatic Urothelial CarcinomaRecruiting
Est. primary completion 2028-01-31 · NCT07393542 · CT.gov ↗
What to watch
February 2028 (4)
Phase 2Cervical CancerNot yet recruiting
Est. primary completion 2028-02 · NCT06149767 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-02-01 · NCT07398560 · CT.gov ↗
What to watch
Phase 2Adebrelimab, Adenocarcinoma of GE Junction, Adenocarcinoma of StomachRecruiting
Est. primary completion 2028-02-01 · NCT07353684 · CT.gov ↗
What to watch
Phase 2/3Ovarian Cancer RecurrentRecruiting
Est. primary completion 2028-02-14 · NCT06791460 · CT.gov ↗
What to watch
March 2028 (5)
Phase 3PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast CancerRecruiting
Est. primary completion 2028-03 · NCT07111832 · CT.gov ↗
What to watch
Phase 2Thymic CarcinomaNot yet recruiting
Est. primary completion 2028-03-01 · NCT07479628 · CT.gov ↗
What to watch
Phase 2Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-03-01 · NCT06339619 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-03-30 · NCT07200154 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-03-30 · NCT07824882 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3Advanced Cervical CancerRecruiting
Est. primary completion 2028-04 · NCT07168200 · CT.gov ↗
What to watch
May 2028 (2)
Phase 2Nasopharyngeal Carcinoma, Nasopharyngeal CancerRecruiting
Est. primary completion 2028-05-01 · NCT06349889 · CT.gov ↗
What to watch
Phase 2Rectal Cancer PatientsActive not recruiting
Est. primary completion 2028-05-29 · NCT07687433 · CT.gov ↗
What to watch
June 2028 (5)
Phase 2HER2-positive Locally Advanced or Metastatic Biliary Tract CancerRecruiting
Est. primary completion 2028-06 · NCT06778031 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-06 · NCT07704645 · CT.gov ↗
What to watch
Phase 2TNBC, Triple Negative Breast Cancer, Brain MetastasasesRecruiting
Est. primary completion 2028-06-30 · NCT07638852 · CT.gov ↗
What to watch
Phase 2Rectal CancersRecruiting
Est. primary completion 2028-06-30 · NCT07622771 · CT.gov ↗
What to watch
Phase 2Advanced Hepatocellular Carcinoma (HCC)Recruiting
Est. primary completion 2028-06-30 · NCT06737913 · CT.gov ↗
What to watch
July 2028 (2)
Phase 2Gastric CanceNot yet recruiting
Est. primary completion 2028-07 · NCT07033143 · CT.gov ↗
What to watch
Phase 2Urothelial Carcinoma, Advanced Urothelial Carcinoma, Urothelial Carcinoma RecurrentRecruiting
Est. primary completion 2028-07-01 · NCT07241793 · CT.gov ↗
What to watch
August 2028 (7)
Phase 1/2Pancreatic Ductal Adenocarcinoma (PDAC), Locally Advanced and Metastatic Pancreatic CancerRecruiting
Est. primary completion 2028-08 · NCT07595172 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-08 · NCT07381543 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerEnrolling by invitation
Est. primary completion 2028-08-01 · NCT06773156 · CT.gov ↗
What to watch
Phase 2Cervical NeoplasmsRecruiting
Est. primary completion 2028-08-01 · NCT07731828 · CT.gov ↗
What to watch
Phase 2Esophageal CancerNot yet recruiting
Est. primary completion 2028-08-01 · NCT07780721 · CT.gov ↗
What to watch
Phase 1/2Pancreatic Cancer, RAS Mutations or AmplificationsNot yet recruiting
Est. primary completion 2028-08-30 · NCT07736612 · CT.gov ↗
What to watch
Phase 2Head and Neck Cancer Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-08-30 · NCT07457346 · CT.gov ↗
What to watch
September 2028 (4)
Phase 2Brain Metastasis From Advanced HER2-negative Breast CancerRecruiting
Est. primary completion 2028-09-10 · NCT06839560 · CT.gov ↗
What to watch
Phase 2Advanced Triple-negative Breast CancerRecruiting
Est. primary completion 2028-09-10 · NCT06771609 · CT.gov ↗
What to watch
Phase 1Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-09-15 · NCT07892625 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-09-26 · NCT07357532 · CT.gov ↗
What to watch
October 2028 (5)
Phase 2/3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-10 · NCT06335355 · CT.gov ↗
What to watch
Phase 2Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR Positive/HER2 Low Breast CancerNot yet recruiting
Est. primary completion 2028-10-15 · NCT07317778 · CT.gov ↗
What to watch
Phase 2Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-10-30 · NCT07796113 · CT.gov ↗
What to watch
Phase 2Locally Advanced Resectable Rectal CancerNot yet recruiting
Est. primary completion 2028-10-31 · NCT07905950 · CT.gov ↗
What to watch
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) AdenocarcinomaNot yet recruiting
Est. primary completion 2028-10-31 · NCT07912957 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Rectal Cancer, Advanced Stage Colorectal Cancer, RadiotherapyRecruiting
Est. primary completion 2028-11-30 · NCT07284992 · CT.gov ↗
What to watch
December 2028 (9)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-12 · NCT06842472 · CT.gov ↗
What to watch
Phase 2Malignant Solid TumorsRecruiting
Est. primary completion 2028-12 · NCT07268040 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07567326 · CT.gov ↗
What to watch
Phase 2Muscle-Invasive Bladder Cancer (MIBC)Not yet recruiting
Est. primary completion 2028-12 · NCT07865611 · CT.gov ↗
What to watch
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2028-12 · NCT07798947 · CT.gov ↗
What to watch
Phase 2Biliary Tract CancerRecruiting
Est. primary completion 2028-12-30 · NCT07569679 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2028-12-31 · NCT06963502 · CT.gov ↗
What to watch
Phase 1Small Cell Lung CancerRecruiting
Est. primary completion 2028-12-31 · NCT07886047 · CT.gov ↗
What to watch
Phase 1/2Pancreatic CancerRecruiting
Est. primary completion 2028-12-31 · NCT07806058 · CT.gov ↗
What to watch
2029 (14)
February 2029 (1)
Phase 1Biliary Tract MalignanciesRecruiting
Est. primary completion 2029-02-23 · NCT06181032 · CT.gov ↗
What to watch
March 2029 (2)
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaNot yet recruiting
Est. primary completion 2029-03-30 · NCT07924332 · CT.gov ↗
What to watch
Phase 2Locally Advanced Cervical CancerNot yet recruiting
Est. primary completion 2029-03-31 · NCT07811375 · CT.gov ↗
What to watch
April 2029 (1)
Phase 2Recurrent/Metastatic Endometrial CancerNot yet recruiting
Est. primary completion 2029-04-01 · NCT06771154 · CT.gov ↗
What to watch
June 2029 (1)
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2029-06 · NCT06474455 · CT.gov ↗
What to watch
July 2029 (1)
Phase 2Small Cell Lung CancerRecruiting
Est. primary completion 2029-07-17 · NCT07559786 · CT.gov ↗
What to watch
August 2029 (2)
Phase 2Gastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction, PD-L1 PositiveNot yet recruiting
Est. primary completion 2029-08-01 · NCT06881017 · CT.gov ↗
What to watch
Phase 2Adebrelimab (SHR-1316), Bevacizumab, Hepatocellular Carcinoma (HCC)Not yet recruiting
Est. primary completion 2029-08-31 · NCT07543783 · CT.gov ↗
What to watch
September 2029 (1)
Phase 2Pancreatic Ductal Adenocarcinoma (PDAC)Not yet recruiting
Est. primary completion 2029-09-01 · NCT07827053 · CT.gov ↗
What to watch
December 2029 (5)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-12 · NCT07836543 · CT.gov ↗
What to watch
Phase 3Advanced Biliary Tract CancerRecruiting
Est. primary completion 2029-12 · NCT07229625 · CT.gov ↗
What to watch
Phase 3Locally Advanced Gastric or Gastroesophageal Junction CancerRecruiting
Est. primary completion 2029-12 · NCT07522151 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2029-12-01 · NCT07890636 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal Cancinoma (NPC), Nasopharangeal CancerNot yet recruiting
Est. primary completion 2029-12-01 · NCT07238569 · CT.gov ↗
What to watch
2030 (8)
May 2030 (2)
Phase 1/2Relapsed or Refractory Peripheral T Cell Lymphoma, NKTCLNot yet recruiting
Est. primary completion 2030-05-29 · NCT07615283 · CT.gov ↗
What to watch
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2030-05-31 · NCT07822542 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2Gastric Adenocarcinoma, Gastroesophageal Adenocarcinoma, Mismatch Repair Deficient or MSI-High Solid Tumors, ImmunotherapyNot yet recruiting
Est. primary completion 2030-06-30 · NCT07266025 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2Liver Cancer (Primary and Metastatic)Not yet recruiting
Est. primary completion 2030-07-01 · NCT07684040 · CT.gov ↗
What to watch
October 2030 (1)
Phase 3Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2030-10 · NCT07118527 · CT.gov ↗
What to watch
November 2030 (1)
Phase 3Systemic Treatment-naïve Pancreatic CancerNot yet recruiting
Est. primary completion 2030-11-30 · NCT07900789 · CT.gov ↗
What to watch
December 2030 (2)
Phase 1/2Advanced Renal Cell CarcinomaRecruiting
Est. primary completion 2030-12 · NCT07239596 · CT.gov ↗
What to watch
Phase 3Triple Negative Breast CancerRecruiting
Est. primary completion 2030-12 · NCT07679360 · CT.gov ↗
What to watch
2031 (6)
February 2031 (1)
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2031-02 · NCT07896005 · CT.gov ↗
What to watch
May 2031 (1)
Phase 2/3Esophageal Squamous Cell Carcinoma (ESCC)Not yet recruiting
Est. primary completion 2031-05 · NCT06861777 · CT.gov ↗
What to watch
September 2031 (1)
Phase 3Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2031-09 · NCT07691762 · CT.gov ↗
What to watch
October 2031 (1)
Phase 2Colorectal CancerActive not recruiting
Est. primary completion 2031-10 · NCT07071714 · CT.gov ↗
What to watch
December 2031 (2)
Phase 2/3Muscular Invasive Bladder Cancer (MIBC)Recruiting
Est. primary completion 2031-12 · NCT06879145 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2031-12-31 · NCT06417554 · CT.gov ↗
What to watch
2032 (2)
November 2032 (1)
Phase 2/3Locally Advanced Resectable Rectal CancerRecruiting
Est. primary completion 2032-11 · NCT07454720 · CT.gov ↗
What to watch
December 2032 (1)
Phase 3Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2032-12-31 · NCT07895238 · CT.gov ↗
What to watch

See the full readout calendar ↗